BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
John Paul Y.C. Shen
Clinical Fellow, Hematology & Oncology
eRA COMMONS USER NAME (credential, e.g., agency login):
jpshen
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and
residency training if applicable.)
DEGREE
INSTITUTION AND LOCATION
(if
MM/YY
FIELD OF STUDY
applicable)
Massachusetts Institute of Technology
Washington University
University of California, San Diego
University of California, San Diego
S.B.
M.D.
-----------
1998-2002
2003-2008
2008-2010
2010- present
Chemistry
Medicine
Internal Medicine
Hematology & Oncology
A. Personal Statement
I am a physician-scientist with a scientific background in chemical biology and clinical training in Internal
Medicine, Hematology, and Oncology. I am currently the Chief Fellow in Hematology & Oncology at UC San
Diego and postdoctoral fellow in the laboratory of Prof. Trey Ideker, in the Departments of Medicine and
Bioengineering at UC San Diego. My research focuses on studying synthetic lethal genetic relationships as a
means to discover new chemotherapeutic drug targets and the development of clinical biomarkers in oncology
by applying novel bioinformatic analysis to data collected by The Cancer Genome Atlas and other repositories
of genomic scale measurements of tumor samples. The ultimate goal of all aspects of my research activity is
the translation of scientific discovery into clinical practice as a means of improving outcomes for our cancer
patients. My prior research as a medical student on the combination of proteasome inhibition and autophagy
inhibition led directly to a phase I clinical trial of bortezomib and hydroxychlorquine in the treatment of Multiple
Myeloma.
B. Positions and Honors
Positions and Employment
2001
Undergraduate Research Assistant, MIT Dept. of Chemistry, Tokmakoff lab, Cambridge, MA
2002
Undergraduate Research Assistant, MIT Dept. of Chemistry, Cambridge, MA
2002-2003
Physics & Math teacher, Saint Louis University High School, Saint Louis, MO
2003
Medical Student Research Assistant, Washington University, Hruz lab, Saint Louis, MO
2004
Medical Student Research Assistant, Harvard University, Schreiber lab, Cambridge, MA
2005-2006
Howard Hughes Research Fellow, Broad Inst., Chemical Biology program, Cambridge, MA
2008-2009
Internal Medicine Intern, UC San Diego, San Diego, CA
2009-2010
Internal Medicine Resident, UC San Diego, San Diego, CA
2010-present Hematology & Oncology Fellow, UC San Diego, San Diego, CA
2012-present Chief Fellow in Hematology & Oncology, UC San Diego, San Diego, CA
Other Experience and Professional Memberships
2004 – Pres American Medical Association
2010 – Pres American Society of Clinical Oncology
2010 – Pres American Society of Hematology
2011 – Pres Board Certified, Internal Medicine
2012 – Pres San Diego County Medical Society
Honors
2002
2006
Phi Beta Kappa Honors Society
Most Valuable Player, MIT Rugby Football Club
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
2007
Dr. Lee & Virginia Harrison Scholarship
C. Selected Peer-reviewed Publications
1. Bradner JE, Mak R, Tanguturi SK, Mazitschek R, Haggarty SJ, Ross K, Chang CY, Bosco J, West N,
Morse E, Lin K, Shen JP, Kwiatkowski NP, Gheldof N, Dekker J, DeAngelo DJ, Carr SA, Schreiber SL,
Golub TR, Ebert BL. Chemical genetic strategy identifies HDAC1 ad HDAC2 as therapeutic targets in
sickle cell disease. Proc Natl Acad Sci. July 2010; 107 (28) 12617-22. . PMID: 20616024
2. Bradner JE, McPherson OM, Mazitschek R, Barnes-Seeman D, Shen JP, Dhaliwal J, Stevenson KE, Duffner
JL, Park SB, Neuberg DS, Nghiem P, Schreiber SL, Koehler AN. A robust small-molecule microarray platform
for screening cell lysates. Chem Biol. May 2006; 5 (5) 493-504. PMID: 16720270
3. Fanta PT, Roeland E, Shen JP, Shimabukuro KA, Hwang M, Ramamoorthy S, Lowy A. Molecular predictors of
treatment response in colon and gastric cancer. J Clin Oncol. Jan 2012; (30) (suppl 4; abstr 619)
4. Shen JP, Divakaran S, Ponduro S, Vogl DT, Amaravadi RK, Bradner JE. The rational for combined
proteasome and autophagy inhibition in multiple myeloma established using novel translational platforms.
Blood (ASH Annual Meeting Abstracts). Nov 2008; 112: 2755
5. Shen JP, Divakaran S, Kuai LT, Wang X, Ong SE, Amaravadi R, Wood J, Carr S, Haggarty S, Bradner JE.
Autophagy as a Target Pathway in Multiple Myeloma: a Forward Chemical Genetic Approach. Blood (ASH
Annual Meeting Abstracts). Nov 2007; 110 (11) 2510.
6. Bradner JE, Shen JP, Perlstein EO, Divakaran S, Greenberg EF, Amaravadi R, Schreiber SL. Discovery and
Characterization of Small Molecule Inhibititors of Autophagy for Cancer Therapy. Blood (ASH Annual Meeting
Abstracts). Nov 2006; 108 (11) 2606.
7. Shen JP, Greenberg EF, Hideshima T, Anderson KC, Schreiber SL, Bradner JE. Targeting the Protein
Degradation Pathway in Multiple Myeloma with Synergistic, Selective Small Molecules. Blood (ASH Annual
Meeting Abstracts). Nov 2005; 106 (11) 2471.
D. Patents
1. Bradner JE, Shen JP, Perlstein E, Rubinsztein D, Sarkar S, Schreiber SL. 2008. Regulating Autophagy.
International Publication Number WO/2008/122038, filed April 2, 2008; published Oct 9, 2008.
E. Research Support
Ongoing:
NIH
5T32 HL086344-04
Ginsberg (PI)
07/01/2011-07/01/2013
Working in laboratory of Trey Ideker using systems biology techniques to study cancer biology
Role: Post-doctoral fellow
Loan Repayment Program
Shen
7/1/12 – 6/30/2014
NIH
Integrative Approach to Translational Ovarian Cancer Research
The goal of this proposal is to discover novel drug targets in ovarian cancer using a synthetic lethal approach,
and to develop biomarkers that will identify patients that will respond to targeted therapies.
Mentor: Dr. Trey Ideker
PHS 398/2590 (Rev. 06/09)
Page
2
Biographical Sketch Format Page